Abstract library

12 results for "Allen".
#2962 90Y- and/or 177Lu-DOTATOC Re-Challenge in Patients with Progressive Neuroendocrine Tumors
Introduction: Most patients treated with PRRT will eventually progress. Previous studies indicated that repeated PRRT is feasible and promising.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. med. Susanne Aberle
Authors: Aberle S, Benz M, Grokovski R, Christ E, ...
#3044 Efficacy of Alkylating Agent Re-challenge after Therapeutic Pause in Metastatic Pancreatic Neuroendocrine Tumors (PanNET)
Introduction: Temozolomide (TMZ) and dacarbazine (DTIC) are alkylating agents (ALK) with antitumor efficacy in metastatic PanNET. Rechallenging ALK following prior efficacy is commonly performed but has not been evaluated.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Louis de Mestier
#3057 Epidemiological Features of Patients with NeuroEndocrine Neoplasms (NENs): Preliminary Results of an Observational Study by the Hellenic Society of Medical Oncology (HeSMO)
Introduction: NENs are rare tumors and can grow in almost all tissues. Regardless histological, molecular and imaging characteristics that are indicative of the primary origin, a significant percentage remain of unknown primary.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD, MSc, PhD Nikolaos Tsoukalas
#2751 Cross-Sectional Study Assessing the Feasibility of Using NET VITALS Communication Tool among Patients with Neuroendocrine Tumors
Introduction: Neuroendocrine tumor (NET) patients have reported ineffective communication with medical providers as a barrier to quality care.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Daneng Li
Authors: Li D, Imbesi G, Yen L, Kim H, ...
#2898 Novel Preclinical Models of Small Bowel Neuroendocrine Tumors for Drug Screening
Introduction: The incidence of neuroendocrine tumors (NETs) from the small bowel (SBNETs) has increased markedly over the past several decades. Many patients with these tumors present with metastatic disease, and research into new treatment options for these tumors have been hindered by the limited number of patient-derived SBNET cell lines and in vivo models available for drug testing.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Assistant Profes Po Hien Ear
Authors: Ear P H, Tran C, Li G, Kaemmer C, ...
#2922 Clinicopathological Characteristics of Borderline Pulmonary Neuroendocrine Neoplasms
Introduction: According to the WHO 2015 classification pulmonary neuroendocrine neoplasms (NENs) are subdivided in carcinoids and neuroendocrine carcinoma (small cell lung carcinoma and large cell neuroendocrine carcinoma (LCNEC)), based on the presence of necrosis and mitotic index (MI). However, in some NENs a discrepancy is observed between grade of differentiation and proliferation rate.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: MD Bregtje Hermans
#710 Characterization of Elderly Patients (≥70 Years) with Neuroendocrine Tumors (NETs)
Introduction: Incidence of NETs increases with age; however, age-specific epidemiologic analyses are lacking.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: María Isabel Sevilla García
Keywords: elderly, NETs
#1527 Induction and Maintenance Regimen with Peptide Receptor Radionuclide Therapy (PRRT) Lu-177-DOTA-TATE (Lu-177) in Patients with Advanced Neuroendocrine Tumours (NET).
Introduction: PRRT using Lu-177 is a treatment option for advanced NETs.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Alexander Mc Ewan
#1779 Large Cell Metastatic Pancreatic Neuroendocrine Carcinoma Treated with Somatostatin Analogues
Introduction: Poorly differentiated neuroendocrine carcinoma of the pancreas are rare malignant tumors with a poor prognosis.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Clinical cases/reports
Presenting Author: Raluca Roxana Grigorescu
#1800 Validation and Comparison between Current Prognostication Systems for Pancreatic Neuroendocrine Neoplasms: Single Institution Experience with 176 Patients
Introduction: Presently, the optimal prognostication system for pancreatic neuroendocrine neoplasms (PNEN) remains unknown.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Assoc Prof Brian Goh
Authors: Goh B, Teo R, Tai D, Allen J, ...
Keywords: PNEN, prognosis